Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?

Area of Science:

• Oncology
• Pharmacology

Background:

• Targeted therapies, specifically tyrosine kinase inhibitors (TKIs), are standard upfront treatment for metastatic renal cell carcinoma (mRCC).
• Recent clinical trials increasingly focus on head-to-head comparisons of TKIs rather than placebo or older treatments.
• A recent phase III trial compared axitinib and sorafenib for upfront mRCC treatment.

Purpose of the Study:

• To critically evaluate the results of a head-to-head phase III trial comparing axitinib and sorafenib in mRCC.
• To conduct a meta-analysis to confirm the potential superiority of axitinib over sorafenib in a larger patient population.
• To highlight the importance of primary endpoint definition in clinical trial outcomes.

Main Methods:

• Discussion of critical aspects of a recently reported head-to-head phase III trial.
• Meta-analysis of axitinib versus sorafenib activity in mRCC patients.
• Evaluation of trial design and endpoint definitions.

Main Results:

• The reported phase III trial compared axitinib directly against sorafenib for upfront mRCC therapy.
• A meta-analysis was performed to assess axitinib's activity compared to sorafenib in a broader patient cohort.
• Preliminary findings suggest axitinib may demonstrate superiority, though endpoint definition is crucial.

Conclusions:

• The comparison of axitinib and sorafenib in mRCC highlights evolving treatment strategies.
• Meta-analysis provides further evidence for evaluating axitinib's efficacy in mRCC.
• Careful consideration of primary endpoints is essential for interpreting trial results accurately.